Hypoparathyroidism-Intellectual Disability-Dysmorphism syndrome (HGID) is a rare inherited disorder characterized by three major components: hypoparathyroidism, resulting in hypocalcemia, intellectual disability, and characteristic dysmorphic features. The disorder results from genetic changes that affect the regulation of the parathyroid glands and calcium metabolism in the body. The syndrome can range in clinical manifestations from mild to severe intellectual disability with varying degrees of dysmorphism, including craniofacial features, minor abnormalities, and more prominent changes.
History of the disease and interesting historical facts
There are many interesting historical facts associated with the syndrome of hypoparathyroidism-intellectual disability-dysmorphism. The first descriptions of similar clinical manifestations are found in medical literature of the early 20th century. In 1970, it was proposed to combine a number of pathologies associated with hypoparathyroidism and mental retardation into a single syndrome. Despite the rarity of the disease, descriptions of its manifestations are mainly focused on the results of observation of individual families with a high predisposition. In recent decades, with the development of genetics, it has been possible to identify the main genetic mutations responsible for the development of this syndrome. This allows for a better understanding of the etiology of the disease and genetic counseling to identify potentially high risks in offspring.
Epidemiology
HGID syndrome is a rare disease: according to epidemiological data, its prevalence is approximately 1 in 100,000 to 1 in 200,000 live births. However, such statistics may vary depending on geographic areas and ethnicity. For example, in some populations, the syndrome is more common due to genetic isolation or specific mutations associated with this population. At the same time, some studies note a high number of undiagnosed cases, which is due to insufficient awareness of this syndrome among medical professionals.
Genetic predisposition to this disease
There are several key genes associated with hypoparathyroidism-intellectual disability-dysmorphism syndrome. The major genes involved include:
- GCM2: Mutations in this gene can lead to impaired development of the parathyroid glands.
- CASR: Mutations in this gene are associated with impaired calcium regulation and the development of hypoparathyroidism.
- ADCY10: genes responsible for calcium movement and metabolism in the body.
Studies show that these mutations are partially responsible for the phenotypic manifestations characteristic of this syndrome. Transmission of the disease occurs in an autosomal recessive manner, which means that two alleles must be carried to manifest clinical signs.
Risk factors for the development of this disease
Risk factors that contribute to the development of HGID syndrome include:
- Heredity: family history of hypoparathyroidism or mental retardation.
- Genetic predisposition: presence of mutations associated with the syndrome in the family tree.
- Environmental factors: exposure to chemicals such as persistent organic pollutants during pregnancy.
It should also be noted that prenatal factors, including maternal infectious diseases, high doses of radiation and the use of certain medications, can increase the risk of developing the disease in the fetus.
Diagnosis of this disease
Diagnosis of HGID syndrome involves a combination of clinical, laboratory and instrumental studies. The main symptoms that may indicate the syndrome include:
- Hypocalcemic manifestations: convulsions, paresthesia, spasms.
- Intellectual disability: ranging from mild to severe.
- Dysmorphic features: facial skeletal abnormalities, shortened limbs.
Laboratory tests include parathyroid hormone, calcium, phosphorus, and vitamin D levels. Radiologic studies may be needed to rule out osteopathies. Differential diagnosis should include other conditions such as DiGeorge syndrome and primary hypoparathyroidism.
Treatment
Treatment of HGID syndrome is a multi-level approach, including pharmacological therapy and correction of disorders. General treatment is aimed at normalizing calcium and parathyroid hormone levels in the body. Pharmacological therapy usually includes:
- Calcium-containing drugs for the correction of hypocalcemia.
- Vitamin D to improve calcium absorption.
In some cases, surgery may be necessary, such as resection of abnormally positioned parathyroid glands. Other treatments may include physical therapy, psychological support, and educational programs for children with intellectual disabilities.
List of medications used to treat this disease
Drugs used to treat HGID syndrome include:
- Calciferol (vitamin D)
- Calcium gluconate
- Allantoic acid
- Selective calcium metabolism modifiers
Additionally, it is important to take into account individual patient reactions to various medications and to continuously monitor their condition.
Disease monitoring
Monitoring of the patient with HGID syndrome includes regular follow-up examinations to assess the condition of teeth, bones, and blood calcium levels. The prognosis is variable; if therapeutic measures are taken, a satisfactory quality of life can be achieved. However, the absence of adequate treatment can lead to serious complications, including neurodevelopmental disorders, pyramidal disorders, and a high risk of chronic diseases.
Age-related features of the disease
The manifestations of the syndrome can vary significantly depending on the age group. In newborns, pronounced dysmorphic features are often detected. In childhood, the deficits and dysmorphism can affect development and learning. In adolescents, increased attention to self-acceptance and social integration becomes paramount, while in adulthood, nephrological and endocrine complications are possible.
Questions and Answers
- What are the main symptoms of HGID syndrome? The main symptoms include hypocalcemic states, mental retardation, and characteristic dysmorphic manifestations.
- Can HGID syndrome be treated? Yes, treatment is aimed at normalizing calcium and parathyroid hormone levels by prescribing calcium and vitamin D.
- What is the heredity of this disease? The disease is transmitted in an autosomal recessive manner, meaning that both parents must be carriers of the mutation.
- Is it possible to get a correct diagnosis at an early age? Yes, early diagnosis is possible through the use of genetic tests and observation of clinical manifestations.
- What is the life expectancy of patients with this syndrome? With adequate treatment and monitoring, life expectancy is not always reduced, but the prognosis depends on individual factors.
Advice from Dr. Oleg Korzhikov
From a practical perspective, it is important to emphasize that patients with hypoparathyroidism-intellectual disability-dysmorphism syndrome need regular monitoring and supportive care. I would recommend the following:
— Maintain constant monitoring of blood calcium levels to prevent hypocalcemia.
— Maintain active participation in educational programs to assist with integration into society.
— Make regular visits to your endocrinologist to monitor changes and adapt treatment.
— Discuss genetic counseling with your family doctors to understand the risks for future generations.
